{"id":351012,"date":"2025-08-25T20:20:01","date_gmt":"2025-08-25T20:20:01","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-arcus-biosciences\/"},"modified":"2025-08-25T20:20:01","modified_gmt":"2025-08-25T20:20:01","slug":"how-to-buy-arcus-biosciences","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/","title":{"rendered":"Arcus Biosciences, Inc. (RCUS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arcus Biosciences, Inc. (RCUS) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334099,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-351012","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Arcus Biosciences, Inc. (RCUS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arcus Biosciences, Inc. (RCUS) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Arcus Biosciences, Inc. (RCUS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arcus Biosciences, Inc. (RCUS) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Arcus Biosciences, Inc. (RCUS) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin ve bu umut vadeden biyoteknoloji hissesinde ak\u0131ll\u0131 yat\u0131r\u0131m kararlar\u0131 verin; kapsaml\u0131 analizimizle.","description_source":{"label":"Description","type":"textarea","formatted_value":"Arcus Biosciences, Inc. (RCUS) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin ve bu umut vadeden biyoteknoloji hissesinde ak\u0131ll\u0131 yat\u0131r\u0131m kararlar\u0131 verin; kapsaml\u0131 analizimizle."},"intro":"Keskin kanser tedavilerine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Arcus Biosciences (RCUS), bilimsel at\u0131l\u0131mlar\u0131n yat\u0131r\u0131m f\u0131rsatlar\u0131yla bulu\u015ftu\u011fu biyoteknoloji inovasyonunun heyecan verici s\u0131n\u0131r\u0131n\u0131 temsil ediyor. Bu klinik a\u015famadaki \u015firket, hasta bak\u0131m\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrebilecek devrim niteli\u011finde kanser tedavileri geli\u015ftiriyor ve biyoteknoloji alan\u0131n\u0131 anlayan ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in \u00f6nemli getiriler sunabilir.","intro_source":{"label":"Intro","type":"text","formatted_value":"Keskin kanser tedavilerine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Arcus Biosciences (RCUS), bilimsel at\u0131l\u0131mlar\u0131n yat\u0131r\u0131m f\u0131rsatlar\u0131yla bulu\u015ftu\u011fu biyoteknoloji inovasyonunun heyecan verici s\u0131n\u0131r\u0131n\u0131 temsil ediyor. Bu klinik a\u015famadaki \u015firket, hasta bak\u0131m\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrebilecek devrim niteli\u011finde kanser tedavileri geli\u015ftiriyor ve biyoteknoloji alan\u0131n\u0131 anlayan ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in \u00f6nemli getiriler sunabilir."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve Piyasa Konumu<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla, Arcus Biosciences, Inc. (RCUS) NASDAQ borsas\u0131nda <strong>10,53 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. \u015eirket yakla\u015f\u0131k 1,12 milyar $ piyasa de\u011ferine sahip olup, \u00f6nemli b\u00fcy\u00fcme potansiyeline sahip orta \u00f6l\u00e7ekli bir biyoteknoloji oyuncusu konumundad\u0131r.<\/p> <p>Takviminize not edin: <strong>5 Kas\u0131m 2025<\/strong>, RCUS yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in son derece kritik bir tarihtir. \u015eirketin bir sonraki \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcnd\u00fcr ve ge\u00e7mi\u015fte bu t\u00fcr olaylar\u0131n hisse fiyat\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde hareket ettirdi\u011fi g\u00f6r\u00fclm\u00fc\u015ft\u00fcr.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 RCUS Hissesini Genellikle Nas\u0131l Etkiler?<\/h3> <p>Kazan\u00e7 duyurular\u0131 \u00e7evresindeki son performans incelendi\u011finde belirgin bir volatilite paterni ortaya \u00e7\u0131kar:<\/p> <ul> <li><strong>6 A\u011fustos 2025 (2. \u00c7eyrek Kazan\u00e7lar\u0131)<\/strong>: Beklenen -1,16 $ EPS'ye kar\u015f\u0131l\u0131k 0,00 $ EPS raporland\u0131; bu s\u00fcrpriz bir ba\u015far\u0131 olup yat\u0131r\u0131mc\u0131 g\u00fcvenini art\u0131rd\u0131<\/li> <li><strong>6 May\u0131s 2025<\/strong>: -1,02 $ tahminine kar\u015f\u0131l\u0131k -1,14 $ EPS ile beklentiler kar\u015f\u0131lanamad\u0131 ve hisse bask\u0131 alt\u0131nda kald\u0131<\/li> <li><strong>\u00d6nceki \u00e7eyrekler<\/strong>: Kazan\u00e7 tarihlerinde genellikle %5-15 fiyat dalgalanmalar\u0131 g\u00f6zlendi<\/li> <\/ul> <p>Desen a\u00e7\u0131kt\u0131r: RCUS, klinik deneme g\u00fcncellemeleri ve finansal sonu\u00e7lara kar\u015f\u0131 y\u00fcksek duyarl\u0131l\u0131k g\u00f6sterir; bu nedenle kazan\u00e7 tarihleri \u00f6zellikle volatil d\u00f6nemlerdir.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h3>6 Ayl\u0131k Fiyat Yolculu\u011fu: \u0130ni\u015f \u00c7\u0131k\u0131\u015flarla \u0130yile\u015fme \u0130\u015faretleri<\/h3> <p>Mart'tan A\u011fustos 2025'e kadar RCUS hisseleri yat\u0131r\u0131mc\u0131lar\u0131 olduk\u00e7a hareketli bir yolculu\u011fa \u00e7\u0131kard\u0131:<\/p> <table border=\"1\" cellpadding=\"5\" cellspacing=\"0\"> <thead> <tr> <th>Ay<\/th> <th>\u00d6nemli Fiyat Seviyeleri<\/th> <th>Ayl\u0131k De\u011fi\u015fim<\/th> <th>Etkenler<\/th> <\/tr> <\/thead> <tbody> <tr> <td><strong>Mart<\/strong><\/td> <td>Y\u00fcksek: 11,10 $, D\u00fc\u015f\u00fck: 7,56 $<\/td> <td>-27,92%<\/td> <td>Geni\u015f biyoteknoloji sekt\u00f6r\u00fc zay\u0131fl\u0131\u011f\u0131<\/td> <\/tr> <tr> <td><strong>Nisan<\/strong><\/td> <td>Y\u00fcksek: 8,76 $, D\u00fc\u015f\u00fck: 6,50 $<\/td> <td>+11,46%<\/td> <td>Erken iyile\u015fme i\u015faretleri, f\u0131rsat avc\u0131l\u0131\u011f\u0131<\/td> <\/tr> <tr> <td><strong>May\u0131s<\/strong><\/td> <td>Y\u00fcksek: 9,61 $, D\u00fc\u015f\u00fck: 7,06 $<\/td> <td>+2,06%<\/td> <td>\u0130stikrarl\u0131 birikim<\/td> <\/tr> <tr> <td><strong>Haziran<\/strong><\/td> <td>Y\u00fcksek: 10,68 $, D\u00fc\u015f\u00fck: 7,91 $<\/td> <td>-8,85%<\/td> <td>Ralli sonras\u0131 kar realizasyonu<\/td> <\/tr> <tr> <td><strong>Temmuz<\/strong><\/td> <td>Y\u00fcksek: 9,97 $, D\u00fc\u015f\u00fck: 7,92 $<\/td> <td>+12,41%<\/td> <td>Pipeline \u00fczerinde yenilenen iyimserlik<\/td> <\/tr> <tr> <td><strong>A\u011fustos<\/strong><\/td> <td>Mevcut: 10,53 $ aral\u0131\u011f\u0131<\/td> <td>Stabilizasyon<\/td> <td>Bir sonraki kataliz\u00f6rlerin beklenmesi<\/td> <\/tr> <\/tbody> <\/table> <p>Genel e\u011filim, Mart diplerinden kayda de\u011fer bir toparlanmay\u0131 g\u00f6steriyor; hisse fiyat\u0131 Nisan ay\u0131ndaki 6,50 $ taban\u0131ndan yakla\u015f\u0131k <strong>%58<\/strong> y\u00fckseldi. Bu toparlanma seyri, yat\u0131r\u0131mc\u0131lar\u0131n \u015firketin klinik pipeline'\u0131na ve stratejik y\u00f6n\u00fcne artan g\u00fcvenini i\u015faret ediyor.<\/p> <h3>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h3> <p>Mevcut analist konsens\u00fcs\u00fc ve pipeline ilerlemesine dayanarak:<\/p> <p><strong>2025 Y\u0131l Sonu<\/strong>: 12-15 $ aral\u0131\u011f\u0131 (mevcut seviyelerden %14-42 y\u00fckseli\u015f)<\/p> <ul> <li>Beklenen olumlu klinik veri a\u00e7\u0131klamalar\u0131 taraf\u0131ndan desteklenir<\/li> <li>Olas\u0131 ortakl\u0131k duyurular\u0131<\/li> <li><a href=\"https:\/\/stockscan.io\/stocks\/RCUS\/forecast\">Stockscan.io tahminleri<\/a> ortalama 8,19 $ iken Wall Street konsens\u00fcs\u00fc daha iyimser<\/li> <\/ul> <p><strong>2026 Projeksiyonu<\/strong>: 18-22 $ aral\u0131\u011f\u0131 (%71-109 potansiyel kazan\u00e7)<\/p> <ul> <li>Ba\u015far\u0131l\u0131 Faz 3 deneme sonu\u00e7lar\u0131 varsay\u0131m\u0131<\/li> <li>Olas\u0131 d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131<\/li> <li><a href=\"https:\/\/tickernerd.com\/stock\/rcus-forecast\/\">Tickernerd analistleri<\/a> 26 $ hedef belirtiyor<\/li> <\/ul> <p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 30-40 $ aral\u0131\u011f\u0131 (%185-280 b\u00fcy\u00fcme potansiyeli)<\/p> <ul> <li>\u00d6nc\u00fc varl\u0131klar\u0131n ticarile\u015ftirilmesi<\/li> <li>Pazar penetrasyonunun geni\u015fletilmesi<\/li> <li>Ortakl\u0131klardan telif gelirleri<\/li> <\/ul> <p><strong>2030 Vizyonu<\/strong>: 50-70+ $ aral\u0131\u011f\u0131 (%375-565 uzun vadeli de\u011fer art\u0131\u015f\u0131)<\/p> <ul> <li>Birden fazla onaylanm\u0131\u015f \u00fcr\u00fcn<\/li> <li>K\u00fcresel pazar geni\u015flemesi<\/li> <li>B\u00fcy\u00fck ila\u00e7 \u015firketlerinden olas\u0131 sat\u0131n alma ilgisi<\/li> <\/ul> <p><strong>Sonu\u00e7<\/strong>: <strong>G\u00dc\u00c7L\u00dc AL<\/strong> \u00f6nerisi, 3-5 y\u0131ll\u0131k ufku olan risk toleransl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in. Risk-getiri profili mevcut seviyelerde birikimi destekliyor.<\/p> <h3>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h3> <h4>Dikkatle De\u011ferlendirilmesi Gereken Riskler:<\/h4> <ol> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Devam eden Faz 3 denemelerinden olumsuz sonu\u00e7lar hisseyi %50-70 d\u00fc\u015f\u00fcrebilir<\/li> <li><strong>D\u00fczenleyici Gecikmeler<\/strong>: FDA gecikmeleri veya reddi de\u011ferlemeyi ciddi \u015fekilde etkiler<\/li> <li><strong>Nakit Yakma Endi\u015feleri<\/strong>: 174 milyon $ negatif nakit ak\u0131\u015f\u0131 dikkatli izlenmeli<\/li> <li><strong>Rekabetin Artmas\u0131<\/strong>: <a href=\"https:\/\/swingtradebot.com\/news-articles\/22057818-arcus-biosciences-swot-analysis-stocks-potential\">Onkoloji alan\u0131nda yo\u011fun rekabet<\/a><\/li> <li><strong>Piyasa Volatilitesi<\/strong>: 2,07 beta de\u011feri a\u015f\u0131r\u0131 fiyat dalgalanmalar\u0131 anlam\u0131na gelir<\/li> <\/ol> <h4>2025 B\u00fcy\u00fcmesi \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/h4> <ol> <li><a href=\"https:\/\/investors.arcusbio.com\/investors-and-media\/press-releases\/press-release-details\/2025\/Arcus-Biosciences-Reports-Second-Quarter-2025-Financial-Results-and-Provides-a-Pipeline-Update\/default.aspx\">2025 2. \u00c7eyrek sonu\u00e7lar\u0131<\/a> umut verici klinik ilerlemeler g\u00f6sterdi<\/li> <li>Stratejik Ortakl\u0131klar: AstraZeneca i\u015f birli\u011fi do\u011frulama ve kaynak sa\u011fl\u0131yor<\/li> <li>Pazar Konumu: HIF-2\u03b1 inhibit\u00f6r\u00fc lideri olarak artan tan\u0131n\u0131rl\u0131k<\/li> <li>Sekt\u00f6r R\u00fczgarlar\u0131: Biyoteknoloji sekt\u00f6r\u00fcnde yenilenen yat\u0131r\u0131mc\u0131 ilgisi<\/li> <li>Mali Destek: G\u00fc\u00e7l\u00fc bilan\u00e7o Ar-Ge yat\u0131r\u0131mlar\u0131n\u0131 destekliyor<\/li> <\/ol> <h3>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h3> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Riski y\u00f6netmek i\u00e7in portf\u00f6y\u00fcn %1-2'si ile ba\u015flay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Toplu para yerine ayl\u0131k sabit tutarlarda yat\u0131r\u0131m yap\u0131n<\/li> <li><strong>Fiyat Uyar\u0131lar\u0131 Kurun<\/strong>: Ek giri\u015fler i\u00e7in yakla\u015f\u0131k 9,50 $ ve kar realizasyonu i\u00e7in 12 $ seviyelerini takip edin<\/li> <li><strong>Bilgi Edinin<\/strong>: Klinik deneme g\u00fcncellemeleri ve FDA ileti\u015fimlerini takip edin<\/li> <li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc<\/strong>: \"RCUS gibi biyoteknoloji hisseleriyle ticaret yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici at\u0131l\u0131mlar ve ara s\u0131ra laboratuvar patlamalar\u0131. Koruyucu g\u00f6zl\u00fcklerinizi takmay\u0131 unutmay\u0131n!\"<\/li> <\/ol> <h3>\u2705 Ad\u0131m Ad\u0131m: Arcus Biosciences, Inc. (RCUS) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h3> <table border=\"1\" cellpadding=\"5\" cellspacing=\"0\"> <thead> <tr> <th>Ad\u0131m<\/th> <th>\u0130\u015flem<\/th> <th>Neden \u00d6nemli<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Bir Ticaret Platformu Se\u00e7in<\/td> <td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td> <\/tr> <tr> <td>2<\/td> <td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td> <td>Tamamen riske atmaya haz\u0131r oldu\u011funuz miktarla ba\u015flay\u0131n<\/td> <\/tr> <tr> <td>3<\/td> <td>\"RCUS\" Aray\u0131n<\/td> <td>\u015eirket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td> <\/tr> <tr> <td>4<\/td> <td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td> <td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td> <\/tr> <tr> <td>5<\/td> <td>\u0130nceleyin ve Onaylay\u0131n<\/td> <td>Emir detaylar\u0131n\u0131 iki kez kontrol edin<\/td> <\/tr> <\/tbody> <\/table> <h3>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option'un \u00d6ne \u00c7\u0131kma Nedenleri<\/h3> <p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option, RCUS gibi hisselere eri\u015fimi daha ula\u015f\u0131labilir k\u0131lan birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum Para Yat\u0131rma<\/strong>: Sadece 5 $ ile pratik yapmaya ve \u00f6\u011frenmeye ba\u015flayabilirsiniz<\/li> <li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Tek belge y\u00fcklemesiyle KYC s\u00fcreci tamamlan\u0131r<\/li> <li><strong>\u00c7ekim Se\u00e7enekleri<\/strong>: Kripto ve e-c\u00fczdanlar dahil 100'den fazla y\u00f6ntem<\/li> <li><strong>E\u011fitim Kaynaklar\u0131<\/strong>: <a href=\"\/blog\">Pocket Option blog<\/a> \u00fczerinden d\u00fczenli piyasa analizleri<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve d\u00fc\u015f\u00fck giri\u015f engeli, Arcus gibi umut vadeden \u015firketlerde pozisyon olu\u015fturmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p> <h3>\ud83c\udf0d 2025'te Arcus Biosciences: Onkoloji Yenilik\u00e7isi<\/h3> <p>Arcus Biosciences, kanser ara\u015ft\u0131rmalar\u0131 ile ticari ila\u00e7 geli\u015ftirme aras\u0131ndaki heyecan verici kesi\u015fim noktas\u0131nda faaliyet g\u00f6stermektedir. \u015eirket, de\u011ferlemesini y\u00f6nlendiren iki ana varl\u0131kla farkl\u0131la\u015ft\u0131r\u0131lm\u0131\u015f kanser tedavileri yaratmaya odaklanm\u0131\u015ft\u0131r:<\/p> <ul> <li><strong>Casdatifan<\/strong>: B\u00f6brek h\u00fccreli karsinom tedavisi i\u00e7in umut vadeden bir HIF-2\u03b1 inhibit\u00f6r\u00fc<\/li> <li><strong>Domvanalimab<\/strong>: Akci\u011fer ve gastrointestinal kanserlere y\u00f6nelik anti-TIGIT antikoru<\/li> <\/ul> <p>\u015eirketin AstraZeneca ile stratejik i\u015f birli\u011fi, klinik geli\u015ftirme i\u00e7in hem do\u011frulama hem de ek kaynaklar sa\u011flamaktad\u0131r. Birden fazla Faz 3 denemesi devam etmekte olup 2026 y\u0131l\u0131na kadar d\u00fczenli veri ak\u0131\u015f\u0131 beklenmektedir. Arcus, biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131 tan\u0131mlayan y\u00fcksek riskli, y\u00fcksek getirili f\u0131rsat t\u00fcr\u00fcn\u00fc temsil eder.<\/p> <p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: 2025 y\u0131l\u0131nda Arcus Biosciences, casdatifan tek ba\u015f\u0131na veya kombinasyon tedavileri alan 125'ten fazla hasta verisini sundu\u2014b\u00f6brek h\u00fccreli karsinomda bu yeni etki mekanizmas\u0131 i\u00e7in sunulan en b\u00fcy\u00fck veri setlerinden biri.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve Piyasa Konumu<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla, Arcus Biosciences, Inc. (RCUS) NASDAQ borsas\u0131nda <strong>10,53 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. \u015eirket yakla\u015f\u0131k 1,12 milyar $ piyasa de\u011ferine sahip olup, \u00f6nemli b\u00fcy\u00fcme potansiyeline sahip orta \u00f6l\u00e7ekli bir biyoteknoloji oyuncusu konumundad\u0131r.<\/p>\n<p>Takviminize not edin: <strong>5 Kas\u0131m 2025<\/strong>, RCUS yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in son derece kritik bir tarihtir. \u015eirketin bir sonraki \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcnd\u00fcr ve ge\u00e7mi\u015fte bu t\u00fcr olaylar\u0131n hisse fiyat\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde hareket ettirdi\u011fi g\u00f6r\u00fclm\u00fc\u015ft\u00fcr.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 RCUS Hissesini Genellikle Nas\u0131l Etkiler?<\/h3>\n<p>Kazan\u00e7 duyurular\u0131 \u00e7evresindeki son performans incelendi\u011finde belirgin bir volatilite paterni ortaya \u00e7\u0131kar:<\/p>\n<ul>\n<li><strong>6 A\u011fustos 2025 (2. \u00c7eyrek Kazan\u00e7lar\u0131)<\/strong>: Beklenen -1,16 $ EPS&#8217;ye kar\u015f\u0131l\u0131k 0,00 $ EPS raporland\u0131; bu s\u00fcrpriz bir ba\u015far\u0131 olup yat\u0131r\u0131mc\u0131 g\u00fcvenini art\u0131rd\u0131<\/li>\n<li><strong>6 May\u0131s 2025<\/strong>: -1,02 $ tahminine kar\u015f\u0131l\u0131k -1,14 $ EPS ile beklentiler kar\u015f\u0131lanamad\u0131 ve hisse bask\u0131 alt\u0131nda kald\u0131<\/li>\n<li><strong>\u00d6nceki \u00e7eyrekler<\/strong>: Kazan\u00e7 tarihlerinde genellikle %5-15 fiyat dalgalanmalar\u0131 g\u00f6zlendi<\/li>\n<\/ul>\n<p>Desen a\u00e7\u0131kt\u0131r: RCUS, klinik deneme g\u00fcncellemeleri ve finansal sonu\u00e7lara kar\u015f\u0131 y\u00fcksek duyarl\u0131l\u0131k g\u00f6sterir; bu nedenle kazan\u00e7 tarihleri \u00f6zellikle volatil d\u00f6nemlerdir.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h3>6 Ayl\u0131k Fiyat Yolculu\u011fu: \u0130ni\u015f \u00c7\u0131k\u0131\u015flarla \u0130yile\u015fme \u0130\u015faretleri<\/h3>\n<p>Mart&#8217;tan A\u011fustos 2025&#8217;e kadar RCUS hisseleri yat\u0131r\u0131mc\u0131lar\u0131 olduk\u00e7a hareketli bir yolculu\u011fa \u00e7\u0131kard\u0131:<\/p>\n<table border=\"1\" cellpadding=\"5\" cellspacing=\"0\">\n<thead>\n<tr>\n<th>Ay<\/th>\n<th>\u00d6nemli Fiyat Seviyeleri<\/th>\n<th>Ayl\u0131k De\u011fi\u015fim<\/th>\n<th>Etkenler<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Mart<\/strong><\/td>\n<td>Y\u00fcksek: 11,10 $, D\u00fc\u015f\u00fck: 7,56 $<\/td>\n<td>-27,92%<\/td>\n<td>Geni\u015f biyoteknoloji sekt\u00f6r\u00fc zay\u0131fl\u0131\u011f\u0131<\/td>\n<\/tr>\n<tr>\n<td><strong>Nisan<\/strong><\/td>\n<td>Y\u00fcksek: 8,76 $, D\u00fc\u015f\u00fck: 6,50 $<\/td>\n<td>+11,46%<\/td>\n<td>Erken iyile\u015fme i\u015faretleri, f\u0131rsat avc\u0131l\u0131\u011f\u0131<\/td>\n<\/tr>\n<tr>\n<td><strong>May\u0131s<\/strong><\/td>\n<td>Y\u00fcksek: 9,61 $, D\u00fc\u015f\u00fck: 7,06 $<\/td>\n<td>+2,06%<\/td>\n<td>\u0130stikrarl\u0131 birikim<\/td>\n<\/tr>\n<tr>\n<td><strong>Haziran<\/strong><\/td>\n<td>Y\u00fcksek: 10,68 $, D\u00fc\u015f\u00fck: 7,91 $<\/td>\n<td>-8,85%<\/td>\n<td>Ralli sonras\u0131 kar realizasyonu<\/td>\n<\/tr>\n<tr>\n<td><strong>Temmuz<\/strong><\/td>\n<td>Y\u00fcksek: 9,97 $, D\u00fc\u015f\u00fck: 7,92 $<\/td>\n<td>+12,41%<\/td>\n<td>Pipeline \u00fczerinde yenilenen iyimserlik<\/td>\n<\/tr>\n<tr>\n<td><strong>A\u011fustos<\/strong><\/td>\n<td>Mevcut: 10,53 $ aral\u0131\u011f\u0131<\/td>\n<td>Stabilizasyon<\/td>\n<td>Bir sonraki kataliz\u00f6rlerin beklenmesi<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Genel e\u011filim, Mart diplerinden kayda de\u011fer bir toparlanmay\u0131 g\u00f6steriyor; hisse fiyat\u0131 Nisan ay\u0131ndaki 6,50 $ taban\u0131ndan yakla\u015f\u0131k <strong>%58<\/strong> y\u00fckseldi. Bu toparlanma seyri, yat\u0131r\u0131mc\u0131lar\u0131n \u015firketin klinik pipeline&#8217;\u0131na ve stratejik y\u00f6n\u00fcne artan g\u00fcvenini i\u015faret ediyor.<\/p>\n<h3>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h3>\n<p>Mevcut analist konsens\u00fcs\u00fc ve pipeline ilerlemesine dayanarak:<\/p>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: 12-15 $ aral\u0131\u011f\u0131 (mevcut seviyelerden %14-42 y\u00fckseli\u015f)<\/p>\n<ul>\n<li>Beklenen olumlu klinik veri a\u00e7\u0131klamalar\u0131 taraf\u0131ndan desteklenir<\/li>\n<li>Olas\u0131 ortakl\u0131k duyurular\u0131<\/li>\n<li><a href=\"https:\/\/stockscan.io\/stocks\/RCUS\/forecast\">Stockscan.io tahminleri<\/a> ortalama 8,19 $ iken Wall Street konsens\u00fcs\u00fc daha iyimser<\/li>\n<\/ul>\n<p><strong>2026 Projeksiyonu<\/strong>: 18-22 $ aral\u0131\u011f\u0131 (%71-109 potansiyel kazan\u00e7)<\/p>\n<ul>\n<li>Ba\u015far\u0131l\u0131 Faz 3 deneme sonu\u00e7lar\u0131 varsay\u0131m\u0131<\/li>\n<li>Olas\u0131 d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131<\/li>\n<li><a href=\"https:\/\/tickernerd.com\/stock\/rcus-forecast\/\">Tickernerd analistleri<\/a> 26 $ hedef belirtiyor<\/li>\n<\/ul>\n<p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 30-40 $ aral\u0131\u011f\u0131 (%185-280 b\u00fcy\u00fcme potansiyeli)<\/p>\n<ul>\n<li>\u00d6nc\u00fc varl\u0131klar\u0131n ticarile\u015ftirilmesi<\/li>\n<li>Pazar penetrasyonunun geni\u015fletilmesi<\/li>\n<li>Ortakl\u0131klardan telif gelirleri<\/li>\n<\/ul>\n<p><strong>2030 Vizyonu<\/strong>: 50-70+ $ aral\u0131\u011f\u0131 (%375-565 uzun vadeli de\u011fer art\u0131\u015f\u0131)<\/p>\n<ul>\n<li>Birden fazla onaylanm\u0131\u015f \u00fcr\u00fcn<\/li>\n<li>K\u00fcresel pazar geni\u015flemesi<\/li>\n<li>B\u00fcy\u00fck ila\u00e7 \u015firketlerinden olas\u0131 sat\u0131n alma ilgisi<\/li>\n<\/ul>\n<p><strong>Sonu\u00e7<\/strong>: <strong>G\u00dc\u00c7L\u00dc AL<\/strong> \u00f6nerisi, 3-5 y\u0131ll\u0131k ufku olan risk toleransl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in. Risk-getiri profili mevcut seviyelerde birikimi destekliyor.<\/p>\n<h3>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h3>\n<h4>Dikkatle De\u011ferlendirilmesi Gereken Riskler:<\/h4>\n<ol>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Devam eden Faz 3 denemelerinden olumsuz sonu\u00e7lar hisseyi %50-70 d\u00fc\u015f\u00fcrebilir<\/li>\n<li><strong>D\u00fczenleyici Gecikmeler<\/strong>: FDA gecikmeleri veya reddi de\u011ferlemeyi ciddi \u015fekilde etkiler<\/li>\n<li><strong>Nakit Yakma Endi\u015feleri<\/strong>: 174 milyon $ negatif nakit ak\u0131\u015f\u0131 dikkatli izlenmeli<\/li>\n<li><strong>Rekabetin Artmas\u0131<\/strong>: <a href=\"https:\/\/swingtradebot.com\/news-articles\/22057818-arcus-biosciences-swot-analysis-stocks-potential\">Onkoloji alan\u0131nda yo\u011fun rekabet<\/a><\/li>\n<li><strong>Piyasa Volatilitesi<\/strong>: 2,07 beta de\u011feri a\u015f\u0131r\u0131 fiyat dalgalanmalar\u0131 anlam\u0131na gelir<\/li>\n<\/ol>\n<h4>2025 B\u00fcy\u00fcmesi \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/h4>\n<ol>\n<li><a href=\"https:\/\/investors.arcusbio.com\/investors-and-media\/press-releases\/press-release-details\/2025\/Arcus-Biosciences-Reports-Second-Quarter-2025-Financial-Results-and-Provides-a-Pipeline-Update\/default.aspx\">2025 2. \u00c7eyrek sonu\u00e7lar\u0131<\/a> umut verici klinik ilerlemeler g\u00f6sterdi<\/li>\n<li>Stratejik Ortakl\u0131klar: AstraZeneca i\u015f birli\u011fi do\u011frulama ve kaynak sa\u011fl\u0131yor<\/li>\n<li>Pazar Konumu: HIF-2\u03b1 inhibit\u00f6r\u00fc lideri olarak artan tan\u0131n\u0131rl\u0131k<\/li>\n<li>Sekt\u00f6r R\u00fczgarlar\u0131: Biyoteknoloji sekt\u00f6r\u00fcnde yenilenen yat\u0131r\u0131mc\u0131 ilgisi<\/li>\n<li>Mali Destek: G\u00fc\u00e7l\u00fc bilan\u00e7o Ar-Ge yat\u0131r\u0131mlar\u0131n\u0131 destekliyor<\/li>\n<\/ol>\n<h3>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h3>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Riski y\u00f6netmek i\u00e7in portf\u00f6y\u00fcn %1-2&#8217;si ile ba\u015flay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Toplu para yerine ayl\u0131k sabit tutarlarda yat\u0131r\u0131m yap\u0131n<\/li>\n<li><strong>Fiyat Uyar\u0131lar\u0131 Kurun<\/strong>: Ek giri\u015fler i\u00e7in yakla\u015f\u0131k 9,50 $ ve kar realizasyonu i\u00e7in 12 $ seviyelerini takip edin<\/li>\n<li><strong>Bilgi Edinin<\/strong>: Klinik deneme g\u00fcncellemeleri ve FDA ileti\u015fimlerini takip edin<\/li>\n<li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc<\/strong>: &#8220;RCUS gibi biyoteknoloji hisseleriyle ticaret yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici at\u0131l\u0131mlar ve ara s\u0131ra laboratuvar patlamalar\u0131. Koruyucu g\u00f6zl\u00fcklerinizi takmay\u0131 unutmay\u0131n!&#8221;<\/li>\n<\/ol>\n<h3>\u2705 Ad\u0131m Ad\u0131m: Arcus Biosciences, Inc. (RCUS) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h3>\n<table border=\"1\" cellpadding=\"5\" cellspacing=\"0\">\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Tamamen riske atmaya haz\u0131r oldu\u011funuz miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;RCUS&#8221; Aray\u0131n<\/td>\n<td>\u015eirket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Emir detaylar\u0131n\u0131 iki kez kontrol edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option&#8217;un \u00d6ne \u00c7\u0131kma Nedenleri<\/h3>\n<p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option, RCUS gibi hisselere eri\u015fimi daha ula\u015f\u0131labilir k\u0131lan birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum Para Yat\u0131rma<\/strong>: Sadece 5 $ ile pratik yapmaya ve \u00f6\u011frenmeye ba\u015flayabilirsiniz<\/li>\n<li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Tek belge y\u00fcklemesiyle KYC s\u00fcreci tamamlan\u0131r<\/li>\n<li><strong>\u00c7ekim Se\u00e7enekleri<\/strong>: Kripto ve e-c\u00fczdanlar dahil 100&#8217;den fazla y\u00f6ntem<\/li>\n<li><strong>E\u011fitim Kaynaklar\u0131<\/strong>: <a href=\"\/blog\">Pocket Option blog<\/a> \u00fczerinden d\u00fczenli piyasa analizleri<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve d\u00fc\u015f\u00fck giri\u015f engeli, Arcus gibi umut vadeden \u015firketlerde pozisyon olu\u015fturmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p>\n<h3>\ud83c\udf0d 2025&#8217;te Arcus Biosciences: Onkoloji Yenilik\u00e7isi<\/h3>\n<p>Arcus Biosciences, kanser ara\u015ft\u0131rmalar\u0131 ile ticari ila\u00e7 geli\u015ftirme aras\u0131ndaki heyecan verici kesi\u015fim noktas\u0131nda faaliyet g\u00f6stermektedir. \u015eirket, de\u011ferlemesini y\u00f6nlendiren iki ana varl\u0131kla farkl\u0131la\u015ft\u0131r\u0131lm\u0131\u015f kanser tedavileri yaratmaya odaklanm\u0131\u015ft\u0131r:<\/p>\n<ul>\n<li><strong>Casdatifan<\/strong>: B\u00f6brek h\u00fccreli karsinom tedavisi i\u00e7in umut vadeden bir HIF-2\u03b1 inhibit\u00f6r\u00fc<\/li>\n<li><strong>Domvanalimab<\/strong>: Akci\u011fer ve gastrointestinal kanserlere y\u00f6nelik anti-TIGIT antikoru<\/li>\n<\/ul>\n<p>\u015eirketin AstraZeneca ile stratejik i\u015f birli\u011fi, klinik geli\u015ftirme i\u00e7in hem do\u011frulama hem de ek kaynaklar sa\u011flamaktad\u0131r. Birden fazla Faz 3 denemesi devam etmekte olup 2026 y\u0131l\u0131na kadar d\u00fczenli veri ak\u0131\u015f\u0131 beklenmektedir. Arcus, biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131 tan\u0131mlayan y\u00fcksek riskli, y\u00fcksek getirili f\u0131rsat t\u00fcr\u00fcn\u00fc temsil eder.<\/p>\n<p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: 2025 y\u0131l\u0131nda Arcus Biosciences, casdatifan tek ba\u015f\u0131na veya kombinasyon tedavileri alan 125&#8217;ten fazla hasta verisini sundu\u2014b\u00f6brek h\u00fccreli karsinomda bu yeni etki mekanizmas\u0131 i\u00e7in sunulan en b\u00fcy\u00fck veri setlerinden biri.<\/p>\n"},"faq":[{"question":"Arcus Biosciences hisseleri nereden al\u0131nabilir?","answer":"Arcus Biosciences hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve ticaret platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"RCUS hisseleri i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 se\u00e7ilen platforma ba\u011fl\u0131d\u0131r ancak Pocket Option gibi platformlarda 5 $ gibi d\u00fc\u015f\u00fck bir miktarla ba\u015flayabilirsiniz."},{"question":"Arcus Biosciences'in klinik denemeleri ne zaman sonu\u00e7lanacak?","answer":"\u015eirketin birden fazla Faz 3 denemesi devam etmekte olup, \u00f6nemli sonu\u00e7lar 2025 ve 2026 y\u0131llar\u0131nda a\u00e7\u0131klanmas\u0131 beklenmektedir."},{"question":"RCUS hisseleri ne kadar risklidir?","answer":"RCUS hisseleri y\u00fcksek volatiliteye sahiptir ve klinik deneme sonu\u00e7lar\u0131 ile d\u00fczenleyici geli\u015fmelerden etkilenebilir; bu nedenle risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur."},{"question":"Arcus Biosciences'in gelecekteki b\u00fcy\u00fcme potansiyeli nedir?","answer":"Analist tahminlerine g\u00f6re 2025-2030 aras\u0131nda hisse fiyat\u0131nda %375-565 aras\u0131nda uzun vadeli de\u011fer art\u0131\u015f\u0131 beklenmektedir, \u00f6zellikle ba\u015far\u0131l\u0131 klinik sonu\u00e7lar ve ticarile\u015fme ile."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Arcus Biosciences hisseleri nereden al\u0131nabilir?","answer":"Arcus Biosciences hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve ticaret platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"RCUS hisseleri i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 se\u00e7ilen platforma ba\u011fl\u0131d\u0131r ancak Pocket Option gibi platformlarda 5 $ gibi d\u00fc\u015f\u00fck bir miktarla ba\u015flayabilirsiniz."},{"question":"Arcus Biosciences'in klinik denemeleri ne zaman sonu\u00e7lanacak?","answer":"\u015eirketin birden fazla Faz 3 denemesi devam etmekte olup, \u00f6nemli sonu\u00e7lar 2025 ve 2026 y\u0131llar\u0131nda a\u00e7\u0131klanmas\u0131 beklenmektedir."},{"question":"RCUS hisseleri ne kadar risklidir?","answer":"RCUS hisseleri y\u00fcksek volatiliteye sahiptir ve klinik deneme sonu\u00e7lar\u0131 ile d\u00fczenleyici geli\u015fmelerden etkilenebilir; bu nedenle risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur."},{"question":"Arcus Biosciences'in gelecekteki b\u00fcy\u00fcme potansiyeli nedir?","answer":"Analist tahminlerine g\u00f6re 2025-2030 aras\u0131nda hisse fiyat\u0131nda %375-565 aras\u0131nda uzun vadeli de\u011fer art\u0131\u015f\u0131 beklenmektedir, \u00f6zellikle ba\u015far\u0131l\u0131 klinik sonu\u00e7lar ve ticarile\u015fme ile."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Arcus Biosciences, Inc. (RCUS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arcus Biosciences, Inc. (RCUS) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arcus Biosciences, Inc. (RCUS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arcus Biosciences, Inc. (RCUS) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T20:20:01+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Arcus Biosciences, Inc. (RCUS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arcus Biosciences, Inc. (RCUS) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T20:20:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/\",\"name\":\"Arcus Biosciences, Inc. (RCUS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arcus Biosciences, Inc. (RCUS) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"datePublished\":\"2025-08-25T20:20:01+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arcus Biosciences, Inc. (RCUS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arcus Biosciences, Inc. (RCUS) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Arcus Biosciences, Inc. (RCUS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arcus Biosciences, Inc. (RCUS) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/","og_locale":"tr_TR","og_type":"article","og_title":"Arcus Biosciences, Inc. (RCUS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arcus Biosciences, Inc. (RCUS) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T20:20:01+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Arcus Biosciences, Inc. (RCUS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arcus Biosciences, Inc. (RCUS) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T20:20:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/","name":"Arcus Biosciences, Inc. (RCUS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arcus Biosciences, Inc. (RCUS) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","datePublished":"2025-08-25T20:20:01+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcus-biosciences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Arcus Biosciences, Inc. (RCUS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arcus Biosciences, Inc. (RCUS) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":351015,"slug":"how-to-buy-arcus-biosciences","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Arcus Biosciences, Inc. (RCUS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Arcus Biosciences, Inc. (RCUS)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-arcus-biosciences\/"},"pt_AA":{"locale":"pt_AA","id":351013,"slug":"how-to-buy-arcus-biosciences","post_title":"Como comprar a\u00e7\u00f5es da Arcus Biosciences, Inc. (RCUS) - Investimento em a\u00e7\u00f5es da Arcus Biosciences, Inc. (RCUS)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-arcus-biosciences\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/351012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=351012"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/351012\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334099"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=351012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=351012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=351012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}